Rheumatology Advance Access published online on November 15, 2005
Rheumatology, doi:10.1093/rheumatology/kei193
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Rheumatology, Lund University Hospital, Sweden
* To whom correspondence should be addressed. Objective. To compare antidy responses to 23-valent pneumococcal vaccine (Pneumovax®) in controls and patients with established rheumatoid arthritis (RA) treated with TNF blockers, methotrexate (MTX) or a combination of both. Methods. Patients with RA (n = 149) and healthy controls (n = 47) were vaccinated. Treatment with TNF blockers (etanercept or infliximab) and MTX was given to 50 patients, and 62 patients were treated with TNF blockers alone or with other DMARDs. MTX alone was given to 37 patients. Concentrations of immunoglobulin G (IgG) antibodies against pneumococcal capsular polysaccharides 23F and 6B were measured by enzyme-linked immunoassay before and 4-6 weeks after vaccination. An immune response was defined as a twofold or higher increase in antibody concentration following vaccination. Results. Prevaccination antibody levels for both 23F and 6B were similar in the patient groups. Antibody concentrations after vaccination increased significantly in all groups. Patients treated with TNF blockers without MTX showed better immune responses than those treated with TNF blockers in combination with MTX (P = 0.037 for 23F and P = 0.004 for 6B) or MTX alone (P<0.001 for both 23F and 6B). RA patients given MTX alone had the lowest immune responses. Prednisolone treatment did not influence the responses. Conclusions. Patients treated with TNF blockers and controls showed similar responses to vaccination. In contrast, patients treated with MTX had reduced responses regardless of anti-TNF treatment. The findings do not argue against the use of pneumococcal vaccination in RA patients undergoing treatment with TNF blockers.
Received May 2, 2005
Accepted October 11, 2005
Original Articles
Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis
M. C. Kapetanovic 1 *,
T. Saxne 1,
A. Sjöholm 2,
L. Truedsson 2,
G. Jönsson 3,
and
P. Geborek 1
2 Section of Microbiology, Immunology and Glycobiology, Institute of Laboratory Medicine, Lund University, Sweden
3 Department of Infectious Diseases, Lund University Hospital, Sweden
M. C. Kapetanovic, E-mail: meliha.crnkic{at}reum.lu.se
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L B S Gelinck, A E van der Bijl, W E P Beyer, L G Visser, T W J Huizinga, R A van Hogezand, G F Rimmelzwaan, and F P Kroon The effect of anti-tumour necrosis factor {alpha} treatment on the antibody response to influenza vaccination Ann Rheum Dis, May 1, 2008; 67(5): 713 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Pradeep, R. Watts, and G. Clunie Audit on the uptake of influenza and pneumococcal vaccination in patients with rheumatoid arthritis Ann Rheum Dis, June 1, 2007; 66(6): 837 - 838. [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Kapetanovic, T. Saxne, J.-A. Nilsson, and P. Geborek Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients Rheumatology, April 1, 2007; 46(4): 608 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Doe, S. Pathare, C. A. Kelly, C. R. Heycock, J. Binding, and J. Hamilton Uptake of influenza vaccination in patients on immunosuppressant agents for rheumatological diseases: a follow-up audit of the influence of secondary care Rheumatology, April 1, 2007; 46(4): 715 - 716. [Full Text] [PDF]
|
|
|
|
|
|
C. Kelly and J. Hamilton What kills patients with rheumatoid arthritis? Rheumatology, February 1, 2007; 46(2): 183 - 184. [Full Text] [PDF]
|
|
|
|
|
|
V. Saravanan and C. Kelly Drug-related pulmonary problems in patients with rheumatoid arthritis Rheumatology, July 1, 2006; 45(7): 787 - 789. [Full Text] [PDF]
|
|